Authored by James Sheppard
At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Mr Jorn Aldag performed for UniQure in 2013.
2013 Liftstream Analysis: At the end of 2012, UniQure announced the EMEA had approved Glybera for use making it the first gene therapy approved in the Western World. Mr Aldag’s challenge for 2013 is to convince payers that the drug is worth the rumoured $1 million price tag?
• Convince payers that Glybera really is worth paying
• Ensure the commercial launch of Glybera in runs to plan
• Advance regulatory approval of Glybera in other key markets
2014 Liftstream Verdict: Mr Aldag and UniQure had a relatively successful year, the highlight being the commercialisation agreement between UniQure and Chiesi. The deal saw Chiesi gain European commercial rights to gene therapy product, Glybera. The deal brought in $21m for UniQure as well as potential future royalties. Mr Aldag is the latest biotech CEO to try the US public markets after fling for an IPO which plans to raise $75m on the NASDAQ. 2013 also saw some key executives join UniQure with Christian Meyer (CMO), Hans Christian Rohde (CCO) and Philip Astley-Sparke (President, USA) all arriving to bolster future commercialisation. The question for 2014 remains the same as 2013, can UniQure quickly achieve pricing and reimbursement and move swiftly through the commercialisation?
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email@example.com or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.